Drug Profile


Alternative Names: DCR-M1711; DCR-MYC

Latest Information Update: 17 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dicerna Pharmaceuticals
  • Class Antineoplastics; Small interfering RNA
  • Mechanism of Action Proto oncogene protein c-myc inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatocellular carcinoma; Multiple myeloma; Non-Hodgkin's lymphoma; Pancreatic cancer; Solid tumours

Most Recent Events

  • 03 Aug 2017 Dicerna Pharmaceuticals terminates a phase I trial in Non-Hodgkin's lymphoma, Solid tumours and Multiple myeloma (Second-line therapy or greater) due to sponsor decision in USA (IV) (NCT02110563)
  • 03 Aug 2017 Dicerna Pharmaceuticals terminates a phase-I/II clinical trial due to sponsor decision in Hepatocellular carcinoma (Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA, Singapore and South Korea (IV) (NCT02314052)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top